Tuesday, Esperion Therapeutics ESPR reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million.
The corporate reported an EPS of $0.34, a turnaround from an EPS lack of $(0.79) a yr in the past, beating the consensus of $0.05.
U.S. web product income was $24.8 million, up roughly 46% Y/Y. Collaboration income was $113.0 million, in comparison with $7.3 million a yr in the past, pushed by elevated pill gross sales to worldwide companions and gross sales development inside accomplice territories together with the settlement-related milestone fee.
“We posted retail prescription equal development of 43% year-over-year, generated our highest stage of income but, and ended the quarter with a money steadiness that positions us to capitalize on our new label and ship long-term worth development,” mentioned Sheldon Koenig, President and CEO.
In March, the FDA accredited broad new label expansions for Esperion Therapeutics’ NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets primarily based on CLEAR Outcomes knowledge that embrace indications for cardiovascular threat discount and expanded LDL-C reducing in main and secondary prevention sufferers.
Through the quarter, the corporate initiated new business initiatives to extend affected person consciousness of NEXLETOL and NEXLIZET’s expanded labels. Expanded gross sales power to 150 representatives within the U.S. and developed new promotional supplies and instruments to complement salesforce efforts.
The corporate initiated the know-how switch course of for NILEMDO and NUSTENDI pill manufacturing to Daiichi Sankyo Europe for its territories, which is anticipated to be accomplished within the second half of 2025.
Moreover, as a part of the amended partnership, the corporate licensed Daiichi Sankyo Europe to proceed with commercialization of a triple formulation product comprising bempedoic acid, ezetimibe, and a statin, which, if accredited, has the potential to increase the product’s lifecycle in Europe.
Steerage: Esperion Therapeutics expects fiscal yr 2024 working bills of $225 million-$245 million.
Value Motion: ESPR shares are up 5.20% at $2.23 eventually test Tuesday.
